Skip to NavigationSkip to content

United Therapeutics to acquire SteadyMed for $216 million

Published on 01/05/18 at 09:57am
Image credit: Rich S, https://s3-media3.fl.yelpcdn.com/bphoto/AQISw4zBdazeDL33nisjtw/l.jpg

United Therapeutics is set to acquire speciality pharma firm SteadyMed after it emerged that the pair had signed a definitive merger agreement. The deal is penned for $4.46 per share in cash with an additional $2.63 per share in milestone payments related to the commercialisation of Trevyent. In total, including an overall $75 million in milestone payments, the deal is valued at $216 million.

SteadyMed specialises in the development and commercialisation of treatments for orphan and high-value diseases with unmet parenteral delivery needs. Trevyent, a focal point of the deal, is a developmental drug-device which combines the firm’s disposable PathPump technology with the vasodilatory prostacyclin analogue drug treprostinil, for the subcutaneous treatment of pulmonary arterial hypertension (PAH).

United Therapeutics, who itself focuses on the treatment of PAH and other orphan conditions, is likely to see a big boost to its own portfolio with the closure of the deal.

"We are optimistic about acquiring SteadyMed and adding Trevyent to our pipeline of products to treat PAH," commented Dr Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics. "We are especially impressed with SteadyMed's management team and global supply chain. Trevyent fits in well with our mission, and we look forward to bringing the product to the maximum number of patients as soon as possible."

Jonathan M N Rigby, President and Chief Executive Officer of SteadyMed, also added: "United Therapeutics has always been at the forefront of developing therapies to treat PAH, and we are delighted at the prospect of our companies coming together, as one, to continue that mission. "We believe that this proposed acquisition will help us realise our commitment to bring Trevyent to market to improve the lives of patients with PAH."

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches